Hims & Hers Health, Inc. (HIMS)
Options Bulls Blast Surging Telehealth Stock After Earnings
Hims & Hers Health Inc (NYSE:HIMS) beat top- and bottom-line estimates for the first quarter, with net profits seeing a 300% jump.
2 Reasons Hims & Hers Will Break $50s - Buy Post Earnings
Hims & Hers Health, Inc. impressed with strong Q1 earnings, subscriber growth, and a promising partnership with Novo Nordisk, but didn't guide as well as we all hoped. The two reasons I'm buying are 1. The partnership with Novo should expand to include Ozempic and 2. Oral pill approval from the FDA should be achieved and boost financials. I think we're still at the start of Hims' comeback story, and the stock is still cheap considering its upside potential.
Hims & Hers stock jumps after blowout quarter, long-term guidance stuns Street
Shares of Hims & Hers Health (HIMS) surged 10% on Tuesday morning after the telehealth company posted first-quarter results that far surpassed Wall Street expectations and unveiled an ambitious roadmap targeting $6.5 billion in revenue by 2030. Revenue in the quarter more than doubled to $586 million, up 111% from a year earlier and well ahead of analysts' average estimate of $538.9 million.
Hims & Hers Stock Rises on Fundamentals and Squeeze Potential
There are only a few companies that come around every half-decade or so that really get the gears turning in terms of having the right fundamental makeup for value investors. It just so happens that these companies (when caught early on) are too small to even be on the radar of the bigger sharks in the financial markets, which is where average retail investors get the chance to act on an inherent advantage.
HIMS Earnings Rally, Guidance Powers CEG, DASH Moves Lower
Hims & Hers (HIMS) rallied this morning after earnings, reversing initial selling action following the report. Diane King Hall believes a huge jump in revenue and its Wegovy deal are behind the positive sentiment.
Hims & Hers: Strong Q1 Masks Problematic Long-Term Value Proposition
Hims & Hers Health, Inc.'s Q1 2025 earnings show impressive growth, with revenues up 111% year-on-year and net income rising significantly, but HIMS shares dropped 8% pre-market. The company's success has been heavily tied to access to weight loss drugs like semaglutide; however, the end of the drug shortage period poses challenges. Hims' new partnership with Novo Nordisk aims to sustain growth, but competition from direct-to-consumer platforms raises concerns about long-term differentiation.
HIMS Growth Potential, Weight-loss Drug Pipeline
Raul Shah says Hims & Hers (HIMS) latest earnings report was a win for two reasons: A lot of operating leverage and expanding growth. Raul believes HIMS guidance was "implausible" in his estimation, adding the company will grow faster than even the company anticipates.
Hims & Hers Health, Inc. (HIMS) Q1 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Bill Newby - Head of Investor Relations Andrew Dudum - Co-Founder and Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Maria Ripps - Canaccord Genuity Eric Percher - Nephron Research Ryan MacDonald - Needham Daniel Grosslight - Citi George Hill - Deutsche Bank David Larsen - BTIG Aaron Kessler - Seaport Research Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
Here's What Key Metrics Tell Us About Hims & Hers Health (HIMS) Q1 Earnings
While the top- and bottom-line numbers for Hims & Hers Health (HIMS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hims & Hers Health, Inc. (HIMS) Beats Q1 Earnings and Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.05 per share a year ago.
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health, Inc. reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year.
Hims & Hers Health Revenue Jumps, But Outlook Disappoints
Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook missed Wall Street's expectations.
